Výsledky vyhledávání - "J. Watermill"

514 POSTER A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer

Autor: A. T. Phan, J. Watermill, Alain C. Mita, J. O'Keeffe, S. Zildjian, R. A. Mastico, A. Qin, R. J. Lutz, Anthony W. Tolcher

Publikováno v: European Journal of Cancer Supplements. 6:163

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51d44d8a07bd533cc2a4b2287b57af1c
https://doi.org/10.1016/s1359-6349(08)72448-0

Zobrazit plný text záznamu

The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors

Autor: A. T. Phan, Alain C. Mita, A. Qin, S. Zildjian, J. Watermill, J. O'Keeffe, R. A. Mastico, Anthony W. Tolcher, R. J. Lutz

Publikováno v: Journal of Clinical Oncology. 26:3066-3066

3066 Background: IMGN242 is a targeted anticancer agent in development for treating CanAg-expressing tumors. In a Phase I clinical study, patients with CanAg-expressing solid tumors were treated wi...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1196ab63152bf187c93aa483eb909c77
https://doi.org/10.1200/jco.2008.26.15_suppl.3066

Zobrazit plný text záznamu

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

Autor: A. Qin, Alain C. Mita, Amita Patnaik, John Sarantopoulos, A. Ricart, Monica M. Mita, J. Watermill, Anthony W. Tolcher, R. J. Fram, K. K. Sankhala

Publikováno v: Journal of Clinical Oncology. 25:3062-3062

3062 Background: HuC242-DM4 is a novel, targeted anti-cancer agent in development for the treatment of CanAg-expressing tumors such as carcinomas of the colon and pancreas. The compound is formed by the conjugation of the potent cytotoxic maytansinoi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e8f5db0724fa3f2481a610a310f6e2e
https://doi.org/10.1200/jco.2007.25.18_suppl.3062

Zobrazit plný text záznamu

212 POSTER A Phase I study of huC242-DM4 to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors

Autor: R. J. Fram, S. Sarantopolus, J. Watermill, A. Ricart, Alain C. Mita, Anthony W. Tolcher, S. Zildjian, Amita Patnaik, Monica M. Mita, J. Rodon

Publikováno v: European Journal of Cancer Supplements. 4:66

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02efc9ca7e9411a343f2b2b68452e644
https://doi.org/10.1016/s1359-6349(06)70217-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání